Dithiolsaccharide mucolytic agents and uses thereof
There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a dithiolsaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.
1. A method of decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of Formula II,
wherein Formula II is represented by:
wherein,
R 2 is —OR 2A ;
R 3 is —OR 3A ;
R 4 is OR 4A ;
R 5 is hydrogen;
R 6 is —SH;
R 7 is —OR 7A ;
R 8 is —OR 8A ;
R 9 is —OR 9A ;
R 10 is hydrogen;
R 11 is —SH;
and
R 2A , R 3A , R 4A , R 7A , R 8A , and R 9A are each independently hydrogen or unsubstituted C 1 -C 10 alkyl;
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the subject has mucus accumulation in an airway or on an eye.
3. The method of claim 1 , wherein the compound is
4. The method of claim 1 , wherein the compound is
5. The method of claim 4 , wherein the subject has mucus accumulation in an airway.
6. The method of claim 5 , wherein the airway is in the upper respiratory tract of the subject.
7. The method of claim 5 , wherein the airway is in a nasal passage, paranasal sinus, the pharynx, and/or larynx of the subject.
8. The method of claim 5 , wherein the airway is in the lower respiratory tract of the subject.
9. The method of claim 5 , wherein the airway is in a trachea, main bronchus, lobar bronchus, segmental bronchus, subsegmental bronchus, conducting bronchiole, terminal bronchiole, respiratory bronchiole, alveolar duct, alveolar sac, or alveolus of the subject.
10. The method of claim 5 , wherein the subject has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more complete mucus airway occlusions of one or more airways within one or two lungs in the subject.
11. The method of claim 4 , wherein the subject has mucus accumulation or mucus occlusion in an airway.
12. The method of claim 4 , wherein the subject has chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), asthma, chronic asthma, acute asthma, bronchitis, chronic bronchitis, acute bronchitis, bronchiectasis, traction bronchiectasis, primary ciliary dyskinesia, bronchiolitis, allergic bronchopulmonary aspergillosis, pneumonia, a mechanical ventilator-associated lung injury, sinusitis, chronic rhinitis, acute sinusitis, chronic sinusitis, chronic rhinosinusitis with nasal polyps, chronic rhinosinusitis without nasal polyps, rhinorrhea, or post-nasal drip.
13. The method of claim 4 , wherein the subject has chronic obstructive pulmonary disease (COPD).
14. The method of claim 4 , wherein the subject has cystic fibrosis (CF).
15. The method of claim 4 , wherein the subject has asthma.
16. The method of claim 4 , wherein the subject has cicatricial pemphigoid, tuberculosis, lung cancer, emphysema, influenza, or primary ciliary dyskinesia.
17. The method of claim 4 , wherein the method is for decreasing mucus elasticity in the subject.
18. The method of claim 4 , wherein the method is for decreasing mucus viscosity in the subject.
19. The method of claim 4 , wherein the subject experiences mucociliary clearance to decrease mucus plugging.
20. The method of claim 4 , wherein the subject experiences mucociliary clearance to improve measures of lung function.
21. The method of claim 4 , wherein the subject experiences an improvement in a chest imaging score that quantifies the number of airway mucus plugs.
22. The method of claim 4 , wherein the subject experiences rapid onset of a disorder selected from the group consisting of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), asthma, bronchiectasis, traction bronchiectasis, primary ciliary dyskinesia, bronchiolitis, and allergic bronchopulmonary aspergillosis.
23. A method of decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of Formula II:
wherein Formula II is represented by:
wherein,
R 2 is —OR 2A ;
R 3 is —OR 3A ;
R 4 is —OR 4A ;
R 5 is hydrogen;
R 6 is —SH;
R 7 is —OR 7A ;
R 8 is —OR 8A ;
R 9 is —OR 9A ;
R 10 is hydrogen;
R 11 is —SH;
and
R 2A , R 3A , R 4A , R 7A , R 8A , and R 9A are each independently hydrogen or unsubstituted C 1 -C 10 alkyl;
or a pharmaceutically acceptable salt thereof;
wherein the subject has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more complete mucus airway occlusions of one or more airways within one or two lungs in the subject, or wherein the subject has cicatricial pemphigoid, tuberculosis, lung cancer, emphysema, influenza, or primary ciliary dyskinesia.
24. The method of claim 23 , wherein the compound is
25. The method of claim 23 , wherein the compound is
26. The method of claim 25 , wherein the subject experiences rapid onset of a disorder selected from the group consisting of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), asthma, bronchiectasis, traction bronchiectasis, primary ciliary dyskinesia, bronchiolitis, and allergic bronchopulmonary aspergillosis.
27. A method for treatment of a condition in a subject, comprising administering to a subject in need thereof an effective amount of a compound of Formula II in combination with another therapeutic agent, wherein the therapeutic action of the therapeutic agent is enhanced by decreasing mucus elasticity or decreasing mucus viscosity, wherein the condition is chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), asthma, chronic asthma, acute asthma, bronchitis, chronic bronchitis, acute bronchitis, bronchiectasis, traction bronchiectasis, primary ciliary dyskinesia, bronchiolitis, allergic bronchopulmonary aspergillosis, pneumonia, a mechanical ventilator-associated lung injury, sinusitis, chronic rhinitis, acute sinusitis, chronic sinusitis, chronic rhinosinusitis with nasal polyps, chronic rhinosinusitis without nasal polyps, rhinorrhea, or post-nasal drip; and wherein Formula II is represented by:
wherein,
R 2 is —OR 2A ;
R 3 is —OR 3A ;
R 4 is —OR 4A ;
R 5 is hydrogen;
R 6 is —SH;
R 7 is —OR 7A ;
R 8 is —OR 8A ;
R 9 is —OR 9A ;
R 10 is hydrogen;
R 11 is —SH;
and
R 2A , R 3A , R 4A , R 7A , R 8A , and R 9A are each independently hydrogen or unsubstituted C 1 -C 10 alkyl;
or a pharmaceutically acceptable salt thereof.